{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:32:28Z","timestamp":1787236348171,"version":"build-2736575974"},"reference-count":50,"publisher":"American Society of Hematology","issue":"10","license":[{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is a hereditary red cell disorder with a large disease burden at a global level. In the United States and Europe, medicines may qualify for orphan designation (OD), a regulatory status that provides incentives to boost development. We evaluated the development of new therapies for SCD using data for OD granted in the United States and Europe over the last 2 decades (2000-2021). We analyzed their characteristics, pathophysiological targets, trends, and OD sponsors. We then investigated the approval outcomes, including the phase success rate and reasons for discontinuation across different variables. We identified 57 ODs for SCD: 43 (75.4%) small molecules, 32 (56.1%) for oral administration, and 36 (63.1%) for chronic use to prevent SCD complications. At the end of the study (2021), development of 34 of 57 ODs was completed. Four ODs were approved with a success rate of 11.8%. Products targeting upstream causative events of SCD pathophysiology had a 1.8 higher success rate compared with products targeting disease consequences. Large companies showed a fourfold higher success rate compared with small-medium enterprises. Failures in clinical development were mainly seen in phase 3 for a lack of efficacy on vaso-occlusive crisis as the primary study end point, likely related to variable definitions and heterogeneity of pain scoring and treatment. Both advances in SCD knowledge and regulatory incentives paved the way for new therapies for SCD. Our finding of high failure rates in late-stage clinical development signals the need for better early-stage predictive models, also in the context of meaningful clinical end points.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011730","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T16:59:23Z","timestamp":1711299563000},"page":"2455-2465","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Successes and pitfalls in orphan drug development for sickle cell\u00a0disease"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-994X","authenticated-orcid":false,"given":"Enrico","family":"Costa","sequence":"first","affiliation":[{"name":"1Division of Pharmacoepidemiology and Clinical Pharmacology, World Health Organization Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0639-2389","authenticated-orcid":false,"given":"Antonella","family":"Isgr\u00f2","sequence":"additional","affiliation":[{"name":"2Centralized Procedures Office, Innovation and Pharmaceutical Strategy Division, Italian Medicines Agency, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-4753","authenticated-orcid":false,"given":"Mariane","family":"de Montalembert","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Necker-Enfants Malades Hospital, Assistance Publique-Hopitaux de Paris Centre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7175-1499","authenticated-orcid":false,"given":"Hubert G. M.","family":"Leufkens","sequence":"additional","affiliation":[{"name":"4Emeritus Professor Regulatory Science and Pharmaceutical Policy, Division of Pharmacoepidemiology and Clinical Pharmacoepidemiology, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-0594","authenticated-orcid":false,"given":"Russell E.","family":"Ware","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-777X","authenticated-orcid":false,"given":"Lucia","family":"De Franceschi","sequence":"additional","affiliation":[{"name":"6Department of Medicine, University of Verona & AOUI Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"10091","key":"2024052418405081900_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"2024052418405081900_bib2","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2214-109X(13)70150-5","article-title":"Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000","volume":"2","author":"Piel","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"24","key":"2024052418405081900_bib3","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2024052418405081900_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"22","key":"2024052418405081900_bib5","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1073\/pnas.80.22.6907","article-title":"Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts","volume":"80","author":"Mavilio","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2024052418405081900_bib6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024052418405081900_bib7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/ajh.26286","article-title":"Real-Life experience with hydroxyurea in patients with sickle cell disease: results from the prospective ESCORT-HU cohort study","volume":"96","author":"de Montalembert","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"2024052418405081900_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"issue":"9778","key":"2024052418405081900_bib9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"2024052418405081900_bib10","unstructured":"US Food and Drug Administration, Orphan Drug Act, Pub L. No. 97-414, 96 Stat. 2049. Accessed 1 April 2022. https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/orphan-drug-act-relevant-excerpts."},{"key":"2024052418405081900_bib11","unstructured":"Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (consolidated version 8 July 2009). Accessed 1 April 2022. http:\/\/eur-lex.europa.eu\/ LexUriServ\/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF."},{"issue":"10149","key":"2024052418405081900_bib12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","article-title":"Outrageous prices of orphan drugs: a call for collaboration","volume":"392","author":"Luzzatto","year":"2018","journal-title":"Lancet"},{"key":"2024052418405081900_bib13","unstructured":"US Food and Drug Administration\n          . Register of orphan drug designations and approvals. Accessed 4 January 2022. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/."},{"key":"2024052418405081900_bib14","unstructured":"European Commission\n          . Community register of orphan medicinal products. Accessed 4 January 2022. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/reg_od_act.htm?sort=a."},{"issue":"9","key":"2024052418405081900_bib15","doi-asserted-by":"crossref","first-page":"e017358","DOI":"10.1136\/bmjopen-2017-017358","article-title":"Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs","volume":"7","author":"Giannuzzi","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"2024052418405081900_bib16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/cts.12980","article-title":"Approval success rates of drug candidates based on target, action, modality, application, and their combinations","volume":"14","author":"Yamaguchi","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2024052418405081900_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"11","key":"2024052418405081900_bib18","doi-asserted-by":"crossref","first-page":"103342","DOI":"10.1016\/j.drudis.2022.103342","article-title":"Emergent treatments for \u03b2-thalassemia and orphan drug legislations","volume":"27","author":"Costa","year":"2022","journal-title":"Drug Discov Today"},{"issue":"1","key":"2024052418405081900_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","article-title":"Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)","volume":"153","author":"Ataga","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2024052418405081900_bib36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A\u00a0phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024052418405081900_bib45","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.2021.3414","article-title":"Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial","volume":"325","author":"Casella","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"2024052418405081900_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.2022015797","article-title":"A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis","volume":"141","author":"Dampier","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024052418405081900_bib47","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S2352-3026(21)00053-3","article-title":"Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Biemond","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2024052418405081900_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2024052418405081900_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A Phase 3 Trial of l-Glutamine in Sickle Cell Disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2024052418405081900_bib50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"2024052418405081900_bib19","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood.2023021220","article-title":"The challenge of clinical end points in sickle cell disease","volume":"142","author":"Ataga","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024052418405081900_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2024052418405081900_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jcf.2023.07.006","article-title":"Traits, trends and hits of orphan drug designations in cystic fibrosis","volume":"22","author":"Costa","year":"2023","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"2024052418405081900_bib22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2021.12.010","article-title":"Achieving end-to-end success in the clinic: Pfizer\u2019s learnings on R&D productivity","volume":"27","author":"Fernando","year":"2022","journal-title":"Drug Discov Today"},{"issue":"7-8","key":"2024052418405081900_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drudis.2011.10.027","article-title":"Determinants for successful marketing authorisation of orphan medicinal products in the EU","volume":"17","author":"Putzeist","year":"2012","journal-title":"Drug Discov Today"},{"issue":"1","key":"2024052418405081900_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: the need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2024052418405081900_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ajh.26063","article-title":"Impact of sickle cell disease on patients\u2019 daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY)","volume":"96","author":"Osunkwo","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2024052418405081900_bib26","first-page":"183","article-title":"Understanding pain and improving management of sickle cell disease: the PiSCES study","volume":"97","author":"Smith","year":"2005","journal-title":"J\u00a0Natl Med Assoc"},{"key":"2024052418405081900_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-3-50","article-title":"Health related quality of life in sickle cell patients: the PiSCES project","volume":"3","author":"McClish","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"2024052418405081900_bib28","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/pme.12823","article-title":"The number of ratings needed for valid pain assessment in clinical trials: replication and extension","volume":"16","author":"Jensen","year":"2015","journal-title":"Pain Med"},{"issue":"8","key":"2024052418405081900_bib29","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1016\/S2352-3026(23)00096-0","article-title":"Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission","volume":"10","author":"Piel","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"2024052418405081900_bib30","doi-asserted-by":"crossref","first-page":"e12305","DOI":"10.2196\/12305","article-title":"A\u00a0postoperative pain management mobile app (panda) for children at home after discharge: usability and feasibility","volume":"2","author":"Dunsmuir","year":"2019","journal-title":"JMIR Perioper Med"},{"issue":"8","key":"2024052418405081900_bib31","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/healthcare10081506","article-title":"Feasibility and quality validation of a mobile application for enhancing adherence to opioids in sickle cell disease","volume":"10","author":"Sop","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2024052418405081900_bib32","doi-asserted-by":"crossref","first-page":"e40844","DOI":"10.2196\/40844","article-title":"mHealth intervention for improving pain, quality of life, and functional disability in patients with chronic pain: systematic review","volume":"11","author":"Moreno-Ligero","year":"2023","journal-title":"JMIR Mhealth Uhealth"},{"issue":"10","key":"2024052418405081900_bib33","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1007\/s00520-021-06146-4","article-title":"Leveraging mobile health technology and research methodology to optimize patient education and self-management support for advanced cancer pain","volume":"29","author":"Azizoddin","year":"2021","journal-title":"Support Care Cancer"},{"issue":"8","key":"2024052418405081900_bib34","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2024052418405081900_bib37","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/bloodadvances.2019000882","article-title":"End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2024052418405081900_bib38","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/bloodadvances.2019000883","article-title":"End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv"},{"key":"2024052418405081900_bib39","doi-asserted-by":"crossref","first-page":"106161","DOI":"10.1016\/j.cct.2020.106161","article-title":"Accelerated approval of Oxbryta\u00ae (voxelotor): a case study on novel endpoint selection in sickle cell disease","volume":"98","author":"Lehrer-Graiwer","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"2024052418405081900_bib40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2141.2011.08961.x","article-title":"Biomarkers in sickle cell disease","volume":"156","author":"Rees","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"2024052418405081900_bib41","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMp1700446","article-title":"Accelerated approval and expensive drugs: a challenging combination","volume":"376","author":"Gellad","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2024052418405081900_bib42","unstructured":"US Food and Drug Administration. Table\u00a0of surrogate endpoints that were the basis of drug approval or licensure. Accessed 4 January 2022. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure."},{"issue":"1","key":"2024052418405081900_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2471\/BLT.23.289731","article-title":"Uptake of orphan drugs in the WHO essential medicines lists","volume":"102","author":"Costa","year":"2024","journal-title":"Bull World Health Organ"},{"key":"2024052418405081900_bib44","doi-asserted-by":"crossref","first-page":"p386","DOI":"10.1136\/bmj.p386","article-title":"Advance the African medicines agency to benefit health and economic development","volume":"380","author":"Sidib\u00e9","year":"2023","journal-title":"BMJ"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2455\/2226447\/blooda_adv-2023-011730-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/10\/2455\/2226447\/blooda_adv-2023-011730-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T14:41:16Z","timestamp":1716561676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/10\/2455\/515444\/Successes-and-pitfalls-in-orphan-drug-development"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011730","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}